Drugs / INTERCEPT Plasma
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02295501 | Dec 2014 → Dec 2020 | Ebola hemorrhagic fever | Cerus Corporation | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INTERCEPT Plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02295501 ↗ |